ROCKVILLE, Md., Aug. 27, 2019 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced that an interim trial update from the
RGX-314 Phase I/IIa clinical trial for the treatment of wet
age-related macular degeneration (wet AMD) will be reported during
a presentation at the Retina Subspecialty Day program of the
American Academy of Ophthalmology (AAO) 2019 Annual Meeting in
San Francisco, CA. The results
will be presented by Dr. Jeffrey S.
Heier, M.D., Co-President and Director of Retina Research at
Ophthalmic Consultants of Boston,
and primary investigator for the trial. Dr. Heier will present the
interim results that include data for all five dose
cohorts.
"We are excited by the previously announced positive interim
data from the Phase I/IIa RGX-314 trial and the potential of NAV
gene therapy as a one-time treatment for wet AMD, and we look
forward to the presentation of data from all five dose cohorts from
the Phase I/IIa clinical trial in wet AMD at the upcoming AAO
meeting," said Steve Pakola, M.D.,
Senior Vice President and Chief Medical Officer of REGENXBIO.
Details of the presentation are as follows:
Title: Results of Cohorts 1-5 for the RGX-314 Phase
I/IIa Study of Gene Therapy for Neovascular wAMD
Presenter: Jeffrey S. Heier, M.D., Co-President and
Director of Retina Research at Ophthalmic Consultants of
Boston
Session date/time: Friday, October 11, 2019,
4:18 p.m. PT / 7:18 p.m. ET
Session title: RET11 – Section VIII: Late Breaking
Developments, Part 1
Room: Moscone Center, WEST 3002
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Forward-Looking Statements
This press release includes "forward-looking statements," within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements express a belief, expectation or
intention and are generally accompanied by words that convey
projected future events or outcomes such as "believe," "may,"
"will," "estimate," "continue," "anticipate," "design," "intend,"
"expect," "could," "plan," "potential," "predict," "seek,"
"should," "would" or by variations of such words or by similar
expressions. The forward-looking statements include statements
relating to, among other things, REGENXBIO's future operations and
clinical trials. REGENXBIO has based these forward-looking
statements on its current expectations and assumptions and analyses
made by REGENXBIO in light of its experience and its perception of
historical trends, current conditions and expected future
developments, as well as other factors REGENXBIO believes are
appropriate under the circumstances. However, whether actual
results and developments will conform with REGENXBIO's expectations
and predictions is subject to a number of risks and uncertainties,
including the timing of enrollment, commencement and completion and
the success of clinical trials conducted by REGENXBIO, its
licensees and its partners, the timing of commencement and
completion and the success of preclinical studies conducted by
REGENXBIO and its development partners, the timely development and
launch of new products, the ability to obtain and maintain
regulatory approval of product candidates, the ability to obtain
and maintain intellectual property protection for product
candidates and technology, trends and challenges in the business
and markets in which REGENXBIO operates, the size and growth of
potential markets for product candidates and the ability to serve
those markets, the rate and degree of acceptance of product
candidates, and other factors, many of which are beyond the control
of REGENXBIO. Refer to the "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" sections of REGENXBIO's Annual Report on Form 10-K for
the year ended December 31, 2018, and
comparable "risk factors" sections of REGENXBIO's Quarterly Reports
on Form 10-Q and other filings, which have been filed with the U.S.
Securities and Exchange Commission (SEC) and are available on the
SEC's website at www.sec.gov. All of the forward-looking statements
made in this press release are expressly qualified by the
cautionary statements contained or referred to herein. The actual
results or developments anticipated may not be realized or, even if
substantially realized, they may not have the expected consequences
to or effects on REGENXBIO or its businesses or operations. Such
statements are not guarantees of future performance and actual
results or developments may differ materially from those projected
in the forward-looking statements. Readers are cautioned not to
rely too heavily on the forward-looking statements contained in
this press release. These forward-looking statements speak only as
of the date of this press release. REGENXBIO does not undertake any
obligation, and specifically declines any obligation, to update or
revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Contacts:
Investors:
Heather Savelle, 212-600-1902
heather@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-interim-phase-iiia-trial-update-for-rgx-314-for-the-treatment-of-wet-amd-at-the-american-academy-of-ophthalmology-2019-annual-meeting-in-october-300907260.html
SOURCE REGENXBIO Inc.